P. Holme

发表

Demonstration of Platelet-Derived Microvesicles in Blood from Patients with Activated Coagulation and Fibrinolysis Using a Filtration Technique and Western Blotting

M. Abdelnoor, P. Holme, N. O. Solum, 1994, Thrombosis and Haemostasis.

Current view and outcome of ITI therapy - A change over time?

J. Astermark, V. Jiménez‐Yuste, T. Lambert, 2016, Thrombosis research.

Combined treatment with APCC (FEIBA®) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A – a two‐centre experience

P. Holme, M. Holmström, H. Tran, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

Shear-induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with a severe stenosis.

K S Sakariassen, P. Holme, N. O. Solum, 1997, Arteriosclerosis, thrombosis, and vascular biology.

Stimulated Glanzmann's thrombasthenia platelets produced microvesicles. Microvesiculation correlates better to exposure of procoagulant surface than to activation of GPIIb-IIIa.

T. Lindahl, P. Holme, N. O. Solum, 1995, Thrombosis and haemostasis.

Hypertension, haematuria and renal functioning in haemophilia – a cross‐sectional study in Europe

C. Combescure, R. Tait, P. Holme, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Increased volume of distribution for recombinant activated factor VII and longer plasma-derived factor VII half-life may explain their long lasting prophylactic effect.

W. V. van Heerde, R. Masereeuw, P. Holme, 2013, Thrombosis research.

Bleeding phenotype of patients with moderate haemophilia A and B assessed by thromboelastometry and thrombin generation

G. Tjønnfjord, P. Holme, E. Berntorp, 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

Investigation of the Optimal Dose aPCC in Reversing the Effect of Factor Xa Inhibitors—An In Vitro Study

P. Holme, J. Fareed, N. H. Schultz, 2021, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor

P. Sandset, P. Holme, H. Tran, 2017, Thrombosis Journal.

The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII in apixaban‐treated patients in vitro

P. Sandset, P. Holme, H. Tran, 2017, Research and practice in thrombosis and haemostasis.

The impact of rivaroxaban on primary hemostasis in patients with venous thrombosis

P. Sandset, P. Holme, C. Henriksson, 2018, Platelets.

Use of thromboelastography and thrombin generation assay to predict clinical phenotype in patients with severe FVII deficiency

G. Tjønnfjord, P. Holme, H. Tran, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Macroscopic hematuria as a risk factor for hypertension in ageing people with hemophilia and a family history of hypertension

R. Tait, P. Holme, P. de Moerloose, 2020, Medicine.

Joint health and treatment modalities in Nordic patients with moderate haemophilia A and B – The MoHem study

J. Astermark, M. Bruzelius, G. Tjønnfjord, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Continuous infusion of coagulation factor concentrates during intensive treatment

G. Tjønnfjord, P. Holme, A. Batorova, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Hypercoagulability in patients with haematological neoplasia: No apparent initiation by tissue factor

P. Iversen, B. Østenstad, P. Sandset, 2008, Thrombosis and Haemostasis.

Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial

A. Waage, G. Tjønnfjord, P. Holme, 2015, The Lancet.

Presentation and management of acute coronary syndromes among adult persons with haemophilia: results of an international, retrospective, 10‐year survey

J. Mahlangu, P. James, P. Holme, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

The influence of rivaroxaban on markers of fibrinolysis and endothelial cell activation/injury in patients with venous thrombosis.

P. Sandset, P. Holme, C. Henriksson, 2019, Thrombosis research.

Comparison of free‐living physical activity measurements between ActiGraph GT3X‐BT and Fitbit Charge 3 in young people with haemophilia

H. Glosli, P. Holme, C. Rueegg, 2022, Haemophilia : the official journal of the World Federation of Hemophilia.

rFVIIa administered by continuous infusion during surgery in patients with severe congenital FVII deficiency

P. Holme, H. Tran, A. Paus, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial

L. Sandvik, P. Sandset, N. Kløw, 2012, The Lancet.

Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial.

L. Sandvik, P. Sandset, N. Kløw, 2016, The Lancet. Haematology.

Catheter‐directed thrombolysis vs. anticoagulant therapy alone in deep vein thrombosis: results of an open randomized, controlled trial reporting on short‐term patency

L. Sandvik, P. Sandset, N. Kløw, 2009, Journal of thrombosis and haemostasis : JTH.

Catheter-directed Venous Thrombolysis in acute iliofemoral vein thrombosis--the CaVenT study: rationale and design of a multicenter, randomized, controlled, clinical trial (NCT00251771).

L. Sandvik, P. Sandset, N. Kløw, 2007, American heart journal.

Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies

G. Tjønnfjord, P. Holme, F. Brosstad, 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

Nordic Haemophilia Council's practical guidelines on diagnosis and management of von Willebrand disease.

P. T. Onundarson, P. Holme, P. Petrini, 2011, Seminars in thrombosis and hemostasis.

Catheter-Directed Thrombolysis for Treatment of Deep Venous Thrombosis in the Upper Extremities

J. Hansen, P. Holme, Kulbir Singh, 2009, CardioVascular and Interventional Radiology.

Recurrent venous thrombosis, post‐thrombotic syndrome and quality of life after catheter‐directed thrombolysis in severe proximal deep vein thrombosis

P. Sandset, P. Holme, A. Rosales, 2011, Journal of thrombosis and haemostasis : JTH.

Shear-induced platelet activation and platelet microparticle formation in native human blood.

P. Holme, N. O. Solum, F. Brosstad, 1998, Thrombosis research.

Immune complexes, innate immunity, and NETosis in ChAdOx1 vaccine-induced thrombocytopenia

T. Nyman, T. Ueland, P. Aukrust, 2021, European heart journal.

The Difference Between Platelet and Plasma FXIII Used to Study the Mechanism of Platelet Microvesicle Formation

P. Holme, N. O. Solum, F. Brosstad, 1993, Thrombosis and Haemostasis.

Platelet‐derived microvesicles and activated platelets express factor Xa activity

P. Holme, N. O. Solum, F. Brosstad, 1995, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Applicability of the European Society of Cardiology Guidelines on the management of acute coronary syndromes to older people with haemophilia A – A modified Delphi consensus by the ADVANCE Working Group

J. Astermark, C. Hermans, P. Fontana, 2022, Haemophilia : the official journal of the World Federation of Hemophilia.

Long‐term outcomes of patients treated with rituximab as second‐line treatment for adult immune thrombocytopenia – Follow‐up of the RITP study

A. Waage, P. Holme, M. Michel, 2020, British journal of haematology.

[Immune thrombocytopenia--pathophysiology and treatment].

G. Tjønnfjord, P. Holme, W. Ghanima, 2010, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

Enhanced activation of platelets with abnormal release of RANTES in human immunodeficiency virus type 1 infection

S. Frøland, P. Aukrust, P. Holme, 1998 .

Non‐genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report

J. Astermark, P. Holme, K. Fijnvandraat, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

Microvesicles Bind Soluble Fibrinogen, Adhere to Immobilized Fibrinogen and Coaggregate with Platelets

P. Holme, N. O. Solum, F. Brosstad, 1998, Thrombosis and Haemostasis.

Activated prothrombin complex concentrate to reverse the factor Xa inhibitor (apixaban) effect before emergency surgery: a case series

R. Lundblad, P. Holme, N. H. Schultz, 2018, Journal of Medical Case Reports.

Tranexamic acid as adjunct therapy to bypassing agents in haemophilia A patients with inhibitors

T. Ueland, G. Tjønnfjord, P. Holme, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Surgery in Inhibitor Patients

P. Holme, 2014 .

FEIBA prophylaxis in haemophilia patients: a clinical update and treatment recommendations

D. Perry, G. Dolan, M. Laffan, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

Genetic Variation in ADAMTS13 is Related to VWF Levels, Atrial Fibrillation and Cerebral Ischemic Events

H. Arnesen, T. Opstad, I. Seljeflot, 2022, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Haemophilic arthropathy: long-term outcomes in 107 primary total knee arthroplasties.

G. Tjønnfjord, P. Holme, Marianne Westberg, 2014, The Knee.

Home treatment with bypassing products in inhibitor patients: a 7.5‐year experience

G. Tjønnfjord, P. Holme, A. Glomstein, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

Clinical outcome and adherence rate in Scandinavian patients with intermediate‐intensity prophylaxis before and after the switch of standard half‐life FVIII products to BAY 81–8973

J. Astermark, P. Holme, E. Berntorp, 2022, Haemophilia : the official journal of the World Federation of Hemophilia.

Management of comorbidities in haemophilia

C. Kempton, M. Makris, P. Holme, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Continuous infusion in haemophilia: current practice in Europe

C. Hermans, P. Holme, K. Fijnvandraat, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

The effect of emicizumab and bypassing agents in patients with hemophilia – An in vitro study

H. Glosli, P. Holme, S. Bjørnsen, 2021, Research and practice in thrombosis and haemostasis.

Should anti‐inhibitor coagulant complex and tranexamic acid be used concomitantly?

L. Valentino, P. Holme, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

Haemophilia early arthropathy detection with ultrasound and haemophilia joint health score in the moderate haemophilia (MoHem) study

J. Astermark, M. Bruzelius, G. Tjønnfjord, 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

The second Team Haemophilia Education Meeting, 2016, Frankfurt, Germany

L. Mantovani, J. Blatny, D. Perry, 2017, European journal of haematology.

The association between health utility and joint status among people with severe haemophilia A: findings from the KAPPA register

J. Astermark, F. Baghaei, P. Holme, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Surgical outcomes in patients with haemophilia A or B receiving extended half‐life recombinant factor VIII and IX Fc fusion proteins: Real‐world experience in the Nordic countries

J. Astermark, F. Baghaei, P. Holme, 2022, Haemophilia : the official journal of the World Federation of Hemophilia.

BAY 94‐9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results

C. Négrier, P. Holme, I. Pabinger, 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

Hematuria in aging men with hemophilia: Association with factor prophylaxis

R. Tait, P. Holme, P. de Moerloose, 2020, Research and practice in thrombosis and haemostasis.

How to compare cardiovascular disease and risk factors in elderly patients with haemophilia with the general population

P. Holme, R. Klamroth, S. Rauchensteiner, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Recovery, survival, and function of transfused platelets and detection of platelet engraftment after allogeneic stem cell transplantation

T. Lyberg, P. Holme, J. Kjeldsen-Kragh, 2012, Transfusion.

Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery

V. Jiménez‐Yuste, E. Rodríguez‐Merchán, P. Holme, 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

Fixed doses of N8‐GP prophylaxis maintain moderate‐to‐mild factor VIII levels in the majority of patients with severe hemophilia A

V. Jiménez‐Yuste, E. Santagostino, M. Carcao, 2019, Research and practice in thrombosis and haemostasis.

Confirmed long‐term safety and efficacy of prophylactic treatment with BAY 94–9027 in severe haemophilia A: final results of the PROTECT VIII extension study

C. Négrier, P. Holme, M. Mancuso, 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

New Inhibitors in the Ageing Population: A Retrospective, Observational, Cohort Study of New Inhibitors in Older People with Hemophilia

J. Astermark, C. Hermans, R. Tait, 2021, Thrombosis and Haemostasis.

Continuous infusion of simoctocog alfa in haemophilia A patients undergoing surgeries

G. Tjønnfjord, P. Holme, 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

Pharmacokinetics and pharmacodynamics of a recombinant fusion protein linking activated coagulation factor VII with human albumin (rVIIa-FP) in patients with congenital FVII deficiency

C. Joch, W. V. van Heerde, P. Holme, 2020, Hematology.

Efficacy and Safety of Bay 94-9027 Is Sustained for 5 Years: Outcomes in 33 Patients in the Protect VIII Extension Study

P. Holme, M. Reding, L. Hvitfeldt Poulsen, 2018, Blood.

European curriculum for thrombosis and haemostasis

J. Astermark, C. Hermans, C. Négrier, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

Bone mineral density in haemophilia – a multicentre study evaluating the impact of different replacement regimens

K. Fischer, P. Holme, J. Klintman, 2022, Haemophilia : the official journal of the World Federation of Hemophilia.

Evaluation of the utility of the ISTH‐BAT in haemophilia carriers: a multinational study

J. Mahlangu, P. James, W. Hopman, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Immune tolerance induction in the era of emicizumab – still the first choice for patients with haemophilia A and inhibitors?

J. Astermark, V. Jiménez‐Yuste, P. Holme, 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

Factor IX antibodies and tolerance in hemophilia B in the Nordic countries - The impact of F9 variants and complications.

J. Astermark, M. Bruzelius, F. Baghaei, 2022, Thrombosis research.

Enhanced activation of platelets with abnormal release of RANTES in human immunodeficiency virus type 1 infection.

S. Frøland, P. Aukrust, P. Holme, 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Glycoprotein IIb-IIIa on platelet-derived microparticles, and microparticle structures studied by electron microscopy, confocal laser microscopy and crossed radio-immunoelectrophoresis.

T. Hovig, P. Holme, N. O. Solum, 1996, Platelets.

Detection of biotinylated proteins in crossed immunoelectrophoresis gels: Studies on platelet membrane receptors and microparticles

P. Holme, T. Pedersen, Nils Olav Solum, 1995, Electrophoresis.

The Fluid-phase SC5b-9 Terminal Complement Complex Binds to the GPIIb/IIIa Complex of Thrombin-stimulated Human Blood Platelets Inhibiting Platelet Aggregation.

T. Halstensen, T. Hovig, P. Holme, 1995, Platelets.

STIM1 R304W causes muscle degeneration and impaired platelet activation in mice.

D. Misceo, H. Westerblad, G. Christensen, 2018, Cell calcium.

A Dominant STIM1 Mutation Causes Stormorken Syndrome

D. Misceo, R. Lyle, A. Stray-Pedersen, 2014, Human mutation.

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

Fridtjof Lund-Johansen, F. Lund-Johansen, G. Tjønnfjord, 2021, The New England journal of medicine.

The elevated prevalence of risk factors for chronic liver disease among ageing people with hemophilia and implications for treatment

R. Tait, P. Holme, E. Berntorp, 2018, Medicine.

Stimulated Glanzmann’s Thrombasthenia Platelets Produce Microvesicles

T. Lindahl, P. Holme, F. Brosstad, 1995, Thrombosis and Haemostasis.

Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome

G. Tjønnfjord, P. Holme, H. Orrem, 2016, Rheumatology.

Pharmacodynamics of recombinant activated factor VII and plasma-derived factor VII in a cohort of severe FVII deficient patients.

W. V. van Heerde, P. Holme, F. Peyvandi, 2013, Thrombosis research.

Adaptation of trustworthy guidelines developed using the GRADE methodology: a novel five-step process.

Thomas Agoritsas, Elie A Akl, Arnljot Tveit, 2014, Chest.

Factors associated with physical activity in young people with haemophilia A on prophylaxis.

H. Glosli, P. Holme, C. Rueegg, 2023, Haemophilia : the official journal of the World Federation of Hemophilia.

Physical activity in Norwegian teenagers and young adults with haemophilia A compared to general population peers

H. Glosli, P. Holme, C. Rueegg, 2023, Haemophilia : the official journal of the World Federation of Hemophilia.

Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: post hoc analysis from the PROTECT VIII study

C. Hermans, G. Di Minno, P. Holme, 2023, Therapeutic advances in hematology.

Vaccine Induced Immune Thrombotic Thrombocytopenia Causing a Severe Form of Cerebral Venous Thrombosis With High Fatality Rate: A Case Series

A. Stray‐Pedersen, P. Holme, A. Aamodt, 2021, Frontiers in Neurology.

Thrombosis and thrombocytopenia after HPV vaccination

B. Gjertsen, P. Holme, N. Vetti, 2021, Journal of Thrombosis and Haemostasis.

[A man in his 80s with muscle stiffness and skin bleeding].

Ø. Bruserud, T. Tvedt, P. Holme, 2014, Tidsskrift for Den Norske Laegeforening.

PB2313: DARATUMUMAB AS A TREATMENT FOR ADULT IMMUNE THROMBOCYTOPENIA: A PHASE II STUDY WITH SAFETY RUN-IN (THE DART STUDY)

T. Tvedt, J. Bussel, P. Holme, 2021, HemaSphere.

Elevated NETs and Calprotectin Levels after ChAdOx1 nCoV-19 Vaccination Correlate with the Severity of Side Effects

P. Holme, M. Fagerhol, G. Hetland, 2022, Vaccines.

Platelet function testing: Current practice among clinical centres in Northern Europe

P. T. Onundarson, P. Holme, R. Lassila, 2022, Haemophilia : the official journal of the World Federation of Hemophilia.

von Willebrand factor, ADAMTS-13, and thrombospondin 1 in relation to clinical outcomes in elderly patients with a recent myocardial infarction

A. Tveit, H. Arnesen, S. Solheim, 2023, Research and practice in thrombosis and haemostasis.

Vaccine associated benign headache and cutaneous hemorrhage after ChAdOx1 nCoV-19 vaccine: A cohort study

P. Holme, A. Aamodt, K. Skagen, 2022, Journal of Stroke and Cerebrovascular Diseases.

Impact of timing of prophylaxis commencement, F8 genotype and age on factor consumption and health‐related quality of life in patients with severe haemophilia A

J. Astermark, P. Holme, E. Berntorp, 2023, Haemophilia : the official journal of the World Federation of Hemophilia.

ULTRASTRUCTURAL ALTERATIONS ON THE PLATELET SURFACE INDUCED BY COMPLEMENT MEMBRANE ATTACK COMPLEX, DEMONSTRATED WITH SERIAL SECTIONS AFTER CRYOFIXATION AND CRYOSUBSTITUTION

R. Dierichs, P. Holme, K. Høgåsen, 2003 .

Anti-PF4/polyanion antibodies in COVID-19 patients are associated with disease severity and pulmonary pathology

T. Ueland, P. Aukrust, O. Skjønsberg, 2022, Platelets.

The Risk of Thromboembolism Associated with Treatment of ITP with Rituximab: Adverse Event Reported in Two Randomized Controlled Trials

T. Tvedt, L. Garabet, P. Holme, 2019, Blood.

Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial.

L. Sandvik, P. Sandset, N. Kløw, 2016, The Lancet. Haematology.

A Dominant STIM1 Mutation Causes Stormorken Syndrome

D. Misceo, R. Lyle, A. Stray-Pedersen, 2014, Human mutation.

Prevalence of COVID‐19 related hospitalizations and mortality in adults aged ≥40 years with haemophilia: A survey from Europe

J. Astermark, C. Hermans, G. Dolan, 2023, Haemophilia : the official journal of the World Federation of Hemophilia.

[Immune thrombocytopenia--pathophysiology and treatment].

G. Tjønnfjord, P. Holme, W. Ghanima, 2010, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

Evaluation of the utility of the ISTH‐BAT in haemophilia carriers: a multinational study

P. Holme, J. Grabell, M. Mingot-Castellano, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

How to compare cardiovascular disease and risk factors in elderly patients with haemophilia with the general population

P. Holme, S. Rauchensteiner, D. Schopohl, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.